CPRX

Catalyst Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · catalystpharma.com

$28.94

Mkt Cap $3.5B

52w Low $19.05 73.2% of range 52w High $32.56

50d MA $24.99 200d MA $22.71

P/E (TTM) 16.4x

EV/EBITDA 6.7x

P/B 3.7x

Debt/Equity 0.0x

ROE 22.5%

P/FCF 13.7x

RSI (14) —

ATR (14) —

Beta 0.66

50d MA $24.99

200d MA $22.71

Avg Volume 1.3M

About

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	0.42	0.68	+61.9%	24.86	-1.5%	+0.1%	-7.2%	-3.9%	-3.8%	-0.7%	—
Nov 5, 2025	AMC	0.51	0.68	+33.3%	21.38	+5.6%	-1.8%	+0.0%	+0.8%	+8.0%	+6.5%	—
Aug 6, 2025	AMC	0.58	0.68	+17.2%	21.79	-0.5%	-9.9%	-8.9%	-9.7%	-6.7%	-7.3%	—
May 7, 2025	AMC	0.53	0.68	+28.3%	23.46	-1.2%	-3.0%	-0.4%	+1.6%	+0.8%	-0.3%	—
Feb 26, 2025	AMC	0.32	0.70	+118.8%	20.58	+8.5%	+5.2%	+11.2%	+8.5%	+7.4%	+6.4%	—
Nov 6, 2024	AMC	0.49	0.57	+16.3%	22.71	+6.6%	+2.4%	+5.4%	+3.3%	+1.5%	+0.4%	—
Aug 7, 2024	AMC	0.42	0.56	+33.3%	16.23	+7.8%	+12.8%	+13.9%	+18.9%	+20.7%	+18.5%	—
May 8, 2024	AMC	0.34	0.38	+11.8%	14.72	+1.0%	+6.3%	+8.3%	+10.2%	+12.0%	+13.2%	—
Feb 28, 2024	AMC	0.48	0.53	+10.4%	14.56	+11.9%	+10.1%	+16.8%	+14.6%	+11.7%	+8.9%	—
Nov 8, 2023	AMC	-0.24	-0.24	+0.0%	12.54	+6.8%	-1.8%	+2.5%	+0.7%	+6.7%	+8.9%	—
Aug 9, 2023	AMC	0.25	0.33	+32.0%	14.12	+6.4%	+6.4%	+5.4%	+5.2%	+6.1%	+4.4%	—
May 10, 2023	AMC	0.32	0.26	-18.8%	17.51	+0.0%	-19.2%	-23.2%	-25.0%	-28.6%	-28.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 3	Citigroup	Maintains	Buy → Buy	—	$23.88	$23.88	+0.0%	+0.2%	+3.4%	+1.8%	+1.5%	+3.8%
Nov 7	Citigroup	Maintains	Buy → Buy	—	$20.99	$21.27	+1.3%	+1.9%	+2.7%	+10.1%	+8.5%	+9.7%
Mar 3	Baird	Maintains	Outperform → Outperform	—	$22.89	$22.89	+0.0%	-2.5%	-3.5%	-4.4%	-5.3%	-4.1%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.66	$21.93	+1.2%	+5.7%	+3.0%	+2.0%	+1.1%	+0.0%
Feb 27	Stephens & Co.	Maintains	Overweight → Overweight	—	$20.58	$22.32	+8.5%	+5.2%	+11.2%	+8.5%	+7.4%	+6.4%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.80	$22.85	+0.2%	-3.9%	-2.6%	-2.7%	+1.1%	-0.6%
Jan 9	BofA Securities	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Nov 11	Truist	Maintains	Buy → Buy	—	$23.93	$24.10	+0.7%	-2.0%	-3.7%	-4.7%	-9.4%	-13.9%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.25	$23.50	+1.1%	+2.9%	+0.9%	-0.9%	-1.9%	-6.7%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.48	$18.83	+1.9%	+4.4%	+6.0%	+4.1%	+7.7%	+7.5%
Aug 9	Citigroup	Maintains	Buy → Buy	—	$18.30	$18.45	+0.8%	+1.0%	+5.5%	+7.0%	+5.1%	+8.8%
Aug 9	Truist	Maintains	Buy → Buy	—	$18.30	$18.45	+0.8%	+1.0%	+5.5%	+7.0%	+5.1%	+8.8%
Jun 6	Oppenheimer	Maintains	Outperform → Outperform	—	$16.31	$16.20	-0.7%	-3.4%	-4.2%	-4.2%	-4.6%	-5.3%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.17	$16.27	+0.6%	+0.1%	-0.8%	+0.9%	-2.5%	-3.4%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.65	$15.83	+1.2%	+1.9%	+3.6%	+5.4%	+6.5%	+4.8%
Mar 27	Oppenheimer	Maintains	Outperform → Outperform	—	$15.75	$15.90	+1.0%	+3.3%	+1.2%	-0.1%	-3.1%	-1.7%
Mar 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$16.62	$16.60	-0.1%	-5.4%	-4.6%	-5.2%	-2.1%	-4.1%
Mar 14	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$16.62	$17.02	+2.4%	-2.6%	-3.3%	-3.2%	-1.4%	+1.7%
Mar 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$16.03	$16.20	+1.1%	+6.1%	+4.1%	+1.5%	-1.1%	+3.8%
Mar 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.03	$16.20	+1.1%	+6.1%	+4.1%	+1.5%	-1.1%	+3.8%
Aug 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$14.60	$14.59	-0.1%	-1.2%	-3.2%	-5.1%	-2.5%	-2.7%
Aug 11	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$15.02	$15.08	+0.4%	-0.9%	-1.1%	-0.3%	-1.9%	-5.2%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.02	$15.08	+0.4%	-0.9%	-1.1%	-0.3%	-1.9%	-5.2%
Jul 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.68	$13.73	+0.4%	-0.1%	-1.0%	-2.0%	-2.7%	-2.5%
Jun 21	Truist	Maintains	Buy → Buy	—	$12.62	$12.85	+1.8%	+5.0%	+4.0%	+4.2%	+2.2%	+4.0%
Jun 21	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$12.62	$12.85	+1.8%	+5.0%	+4.0%	+4.2%	+2.2%	+4.0%
Jun 20	Truist	Maintains	Buy → Buy	—	$12.20	$12.14	-0.5%	+3.4%	+8.6%	+7.6%	+7.8%	+5.7%
May 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.15	$14.16	+0.1%	-4.9%	-7.1%	-11.6%	-11.4%	-13.8%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.92	$15.96	+0.3%	+3.0%	+3.8%	+1.8%	+0.6%	+1.3%
Jan 19	Truist	Maintains	Buy → Buy	—	$20.43	$20.31	-0.6%	-0.8%	+1.8%	-27.8%	-21.1%	-18.1%
Dec 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.60	$18.92	+1.7%	+4.8%	+4.0%	+2.2%	-0.1%	-2.5%
Dec 21	Truist	Maintains	Buy → Buy	—	$18.60	$18.92	+1.7%	+4.8%	+4.0%	+2.2%	-0.1%	-2.5%
Dec 20	Piper Sandler	Maintains	Overweight → Overweight	—	$16.41	$16.80	+2.4%	+13.3%	+18.8%	+17.9%	+15.8%	+13.3%
Aug 24	Roth Capital	Downgrade	Buy → Neutral	—	$14.91	$14.47	-3.0%	-6.3%	-3.8%	-6.0%	-5.3%	-7.0%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.13	$13.10	-0.2%	+1.8%	+5.9%	+8.4%	+6.4%	+4.6%
Aug 11	Truist	Maintains	Buy → Buy	—	$13.13	$13.10	-0.2%	+1.8%	+5.9%	+8.4%	+6.4%	+4.6%
Feb 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.54	$6.56	+0.3%	+6.9%	+12.4%	+13.3%	+21.4%	+15.9%
Mar 18	Roth Capital	Maintains	Buy → Buy	—	$4.23	$4.24	+0.2%	-0.5%	+3.3%	+10.9%	+10.4%	+1.4%
Aug 12	Truist	Maintains	Buy → Buy	—	$3.34	$3.45	+3.3%	+0.6%	+2.1%	+3.9%	+10.5%	+9.0%
May 13	SunTrust Robinson Humphrey	Maintains	Buy → Buy	—	$4.58	$4.63	+1.0%	-4.4%	-7.1%	-0.8%	-0.8%	-6.2%
Feb 14	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.77	$4.89	+2.5%	+0.0%	+7.5%	+7.8%	+9.0%	+9.2%
Dec 13	Piper Sandler	Maintains	Overweight → Overweight	—	$2.40	$2.52	+5.0%	+2.5%	-2.5%	-2.5%	+1.2%	-6.7%
Dec 13	PiperJaffray	Maintains	Overweight → Overweight	—	$2.40	$2.52	+5.0%	+2.5%	-2.5%	-2.5%	+1.2%	-6.7%
Nov 29	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$3.13	$2.98	-4.8%	-11.5%	-19.0%	-23.8%	-26.5%	-28.8%
Sep 21	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$3.14	$3.17	+1.0%	+0.3%	+9.6%	+11.1%	+18.2%	+19.7%
Jul 13	Oppenheimer	Maintains	Outperform → Outperform	—	$3.20	$3.46	+8.1%	+2.2%	+0.9%	-0.9%	-3.8%	-3.8%
Oct 5	PiperJaffray	Upgrade	Neutral → Overweight	—	$1.12	$1.28	+14.3%	+30.4%	+24.1%	+21.4%	+17.9%	+11.6%
Oct 5	Piper Sandler	Upgrade	Neutral → Overweight	—	$1.12	$1.28	+14.3%	+30.4%	+24.1%	+21.4%	+17.9%	+11.6%
Apr 26	PiperJaffray	Downgrade	Overweight → Neutral	—	$1.24	$0.55	-55.6%	-49.2%	-49.2%	-48.8%	-45.2%	-46.5%
Apr 26	Piper Sandler	Downgrade	Overweight → Neutral	—	$1.24	$0.55	-55.6%	-49.2%	-49.2%	-48.8%	-45.2%	-46.5%

Recent Filings

8-K

Unknown — 8-K Filing

This appears to be a technical correction to a previously filed 8-K, suggesting no material business developments were omitted—investors should review the original filing for substantive information.

Mar 19

8-K

Unknown — 8-K Filing

I cannot write a meaningful analyst sentence about this filing because the 8-K summary provided contains only technical XBRL schema metadata rather than actual business event disclosures; an investor cannot assess stock impact without substantive filing content.

Mar 18

8-K

Catalyst Pharmaceutical Inc. -- 8-K Filing

Catalyst Pharmaceutical (CPRX) projects 2026 revenues of $615-645 million with promoted product revenue growth exceeding 20%, demonstrating confidence in its FIRDAPSE and AGAMREE drug franchises.

Feb 25

Data updated apr 25, 2026 2:55am · Source: massive.com